FDA approved.
Proven safe and effective.

 

 

 

 

 

Significant reduction in bleeding with prophylaxis in children and adults7

  • In clinical studies with 59 children treated with prophylaxis:
    • The median annualized bleeding rate (ABR) was 1.9
    • 34 patients (57.6%) had 0 or 1 bleeding episode
  • In clinical studies with 32 adults treated with prophylaxis:
    • The median annualized bleeding rate (ABR) was 0.9
    • 27 patients (84.4%) had 0 or 1 bleeding episode

 

 

 

Bleeding control with on-demand treatment7

  • In clinical studies with 20 adults and 2 adolescents treated with NUWIQ:
    • 91.4% of all bleeds were resolved with just 1 infusion
    • 97% of all bleeds were resolved with 1 or 2 infusions
    • Efficacy for the treatment of bleeds was rated as excellent or good in 94% of bleeds

 

 

 

Control and prevention of bleeding during and after surgery7

  • In clinical studies with 19 patients in 33 surgical procedures:
    • Hemostasis was rated as “excellent” by surgeon and hematologist in 100% of minor surgeries
    • Hemostasis was rated as “excellent” or “good” in 92% of major surgeries